

# Judith M Gottwein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8524142/publications.pdf>

Version: 2024-02-01

49  
papers

2,978  
citations

230014

27  
h-index

232693

48  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2413  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. <i>Journal of Hepatology</i> , 2022, 76, 1051-1061.	1.8	11
2	Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication. <i>Viruses</i> , 2022, 14, 172.	1.5	18
3	High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor. <i>Vaccines</i> , 2022, 10, 249.	2.1	2
4	SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor. <i>Vaccines</i> , 2021, 9, 706.	2.1	14
5	Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0009721.	1.4	58
6	In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 14571.	1.6	53
7	Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. <i>PLoS ONE</i> , 2021, 16, e0255336.	1.1	2
8	Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0268020.	1.4	28
9	Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 <i>In Vitro</i> . <i>Viruses</i> , 2021, 13, 2082.	1.5	18
10	Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. <i>Scientific Reports</i> , 2020, 10, 16261.	1.6	23
11	Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. <i>Vaccines</i> , 2020, 8, 294.	2.1	14
12	Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro. <i>Proceedings (mdpi)</i> , 2020, 50, .	0.2	0
13	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. <i>Hepatology</i> , 2019, 70, 771-787.	3.6	46
14	HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. <i>Journal of Hepatology</i> , 2019, 70, 388-397.	1.8	34
15	Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1a and 1b and Escape Variants. <i>Gastroenterology</i> , 2018, 154, 1435-1448.	0.6	89
16	HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. <i>Gastroenterology</i> , 2018, 154, 2194-2208.e12.	0.6	41
17	Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model. <i>Scientific Reports</i> , 2018, 8, 4619.	1.6	33
18	High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. <i>Scientific Reports</i> , 2018, 8, 17505.	1.6	10

#	ARTICLE	IF	CITATIONS
19	Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. <i>Virology</i> , 2018, 522, 177-192.	1.1	4
20	Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	10
21	Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: <i>In Vitro</i> Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3563-3578.	1.4	25
22	Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. <i>Gastroenterology</i> , 2016, 151, 973-985.e2.	0.6	78
23	Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. <i>Journal of Virology</i> , 2015, 89, 7758-7775.	1.5	26
24	High Reproducibility of ELISPOT Counts from Nine Different Laboratories. <i>Cells</i> , 2015, 4, 21-39.	1.8	20
25	Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7426-7436.	1.4	39
26	Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. <i>Hepatology</i> , 2014, 59, 395-407.	3.6	63
27	Differential Sensitivity of 5'UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1-6 to Protease and NS5A Inhibitors. <i>Gastroenterology</i> , 2014, 146, 812-821.e4.	0.6	58
28	Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. <i>Virology</i> , 2014, 458-459, 190-208.	1.1	20
29	Identification of Alpha Interferon-Induced Envelope Mutations of Hepatitis C Virus <i>In Vitro</i> Associated with Increased Viral Fitness and Interferon Resistance. <i>Journal of Virology</i> , 2013, 87, 12776-12793.	1.5	25
30	Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7. <i>Journal of General Virology</i> , 2013, 94, 2221-2235.	1.3	21
31	Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1a, 2a, and 3a Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1291-1303.	1.4	35
32	Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6034-6049.	1.4	17
33	Cell-culture-derived HCV $\alpha$ a promising vaccine antigen. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 508-509.	8.2	14
34	Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19757-19762.	3.3	109
35	Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1101-10.	3.3	78
36	Recombinant HCV Variants With NS5A From Genotypes 1-7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon- $\alpha$ . <i>Gastroenterology</i> , 2011, 140, 1032-1042.e6.	0.6	132

#	ARTICLE	IF	CITATIONS
37	Differential Efficacy of Protease Inhibitors Against HCV Genotypes 2a, 3a, 5a, and 6a NS3/4A Protease Recombinant Viruses. <i>Gastroenterology</i> , 2011, 141, 1067-1079.	0.6	134
38	Vaccine-Induced Cross-Genotype Reactive Neutralizing Antibodies Against Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2011, 204, 1186-1190.	1.9	91
39	MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4991-4996.	3.3	182
40	Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization. <i>Journal of Virology</i> , 2011, 85, 2224-2234.	1.5	128
41	Efficient Culture Adaptation of Hepatitis C Virus Recombinants with Genotype-Specific Core-NS2 by Using Previously Identified Mutations. <i>Journal of Virology</i> , 2011, 85, 2891-2906.	1.5	67
42	Development and Application of Hepatitis C Reporter Viruses with Genotype 1 to 7 Core-Nonstructural Protein 2 (NS2) Expressing Fluorescent Proteins or Luciferase in Modified JFH1 NS5A. <i>Journal of Virology</i> , 2011, 85, 8913-8928.	1.5	77
43	Novel Infectious cDNA Clones of Hepatitis C Virus Genotype 3a (Strain S52) and 4a (Strain ED43): Genetic Analyses and <i>In Vivo</i> Pathogenesis Studies. <i>Journal of Virology</i> , 2010, 84, 5277-5293.	1.5	122
44	Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. <i>Hepatology</i> , 2009, 49, 364-377.	3.6	333
45	Chapter 2 Cutting the Gordian Knot-Development and Biological Relevance of Hepatitis C Virus Cell Culture Systems. <i>Advances in Virus Research</i> , 2008, 71, 51-133.	0.9	88
46	Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 997-1002.	3.3	167
47	Highly Efficient JFH1-Based Cell Culture System for Hepatitis C Virus Genotype 5a: Failure of Homologous Neutralizing Antibody Treatment to Control Infection. <i>Journal of Infectious Diseases</i> , 2008, 198, 1756-1765.	1.9	101
48	Hepatitis C virus-host cell interactions uncovered. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13215-13216.	3.3	4
49	Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a/2a (S52/JFH1) Viruses. <i>Gastroenterology</i> , 2007, 133, 1614-1626.	0.6	168